[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100115485":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":11,"maxAge":11,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The Chaim Sheba Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: methylphenidate, fluoxetin, risperidone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","methylphenidate, fluoxetin, risperidone","first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Doron Gothelf, MD","CONTACT","972-03-5302663","gothelf@post.tau.ac.il",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Schneider Children's Mediac Center of Israel","RECRUITING","Petah Tikva","49202","Israel","IL",{"type":35,"coordinates":36},"Point",[37,38],34.88747,32.08707,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":11},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof. Doron Gothelf","Principal Investigator","100115485",false,"NCT00768820","The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome","The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors","VCFS","Inclusion Criteria:\n\n* chromosomal deletion proven by FISH examination\n\nExclusion Criteria:","ALL",{"count":55,"type":56},400,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors",[62,63,64],"Velocardiofacial Syndrome","Williams Syndrome","Fragile X Syndrome",[66,67,68,69,70],"Velocardiofacial syndrome","Williams syndrome","fragile X syndrome","cognitive phenotype","psychiatric phenotype","2026-03-17",{"date":73,"type":74},"2026-03-18","ACTUAL",{"date":76,"type":11},"2001-05",{"date":78,"type":56},"2027-08",{"name":5,"class":6},1]